John Hayes

John Hayes has served as Akamis Bio’s Vice President of Finance since March 2025, and brings over twenty years of life science industry finance and accounting experience. Prior to joining Akamis Bio, John was the Vice President of Finance at Intellia Therapeutics, a publicly traded genome editing company developing CRISPR/Cas9-based therapies. At Intellia, John led the Finance and Accounting team and supported the company’s growth from research through clinical trials and commercial readiness, and assisted in multiple rounds of financing, helping raise more than $1B to support the Company’s mission. Prior to joining Intellia, John was the Head of Finance and Corporate Controller at Crestovo, a clinical-stage microbiome company. Prior to Crestovo, John was the Head of FP&A and Financial Reporting at Tetraphase Pharmaceuticals, a publicly traded antibiotics company, and also held senior financial roles at Aveo Oncology and Anika Therapeutics. John began his career in public accounting at PricewaterhouseCoopers and Ernst & Young where he focused on the life sciences industry. John holds a Bachelor of Business Administration (B.B.A.) from the University of Massachusetts, Amherst, with a concentration in accounting, and is a Certified Public Accountant in the Commonwealth of Massachusetts.